MEK/ERK pathway is aberrantly active in Hodgkin disease: A signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival

Blood

Volumn 102, Issue 3, 2003, Pages 1019-1027

  Zheng, Bei ^b   Flumara, Paolo ^b   Li, Yang V ^b   Georgakis, Georgios ^b   Snell, Virginia ^b   Younes, Mamoun ^b   Vauthey, Jean Nicolas ^b   Carbone, Antonino ^b   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BENZYLOXYCARBONYLPHENYLALANYLALANYL FLUOROMETHYL KETONE; CASPASE 8; CASPASE 8 HOMOLOG FLICE INHIBITORY PROTEIN; CASPASE INHIBITOR; CD30 ANTIGEN; CD40 ANTIGEN; CELL PROTEIN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NUCLEAR FACTOR KAPPA B RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN BCL 2; PROTEIN MCL 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GROWTH REGULATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIGAND BINDING; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 0042744812     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3507     Document Type: Article

References (60)

1. Gutkind JS. Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. Sci STKE. 2000;2000:RE1.
2. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22:153-183.
3. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37-40.
4. Dai Y, Yu C, Singh V, et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 2001;61:5106-5115.
5. Vrana JA, Grant S, Dent P. Inhibition of the MAPK pathway abrogates BCL2-mediated survival of leukemia cells after exposure to low-dose ionizing radiation. Radiat Res. 1999;151:559-569.
6. Towatari M, Iida H, Tanimoto M, Iwata H, Hamaguchi M, Saito H. Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia. 1997;11:479-484.
7. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001;108:851-859.
8. Lee JT Jr, McCubrey JA. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia. 2002;16:486-507.
9. Donovan JC, Milic A, Slingerland JM. Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem. 2001;276: 40888-40895.
10. Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH, Murphy LC. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res. 2002;8:1747-1753.
11. Morgan MA, Dolp O, Reuter CW. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood. 2001;97:1823-1834.
12. Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem. 2001;276:16484-16490.
13. Persons DL, Yazlovitskaya EM, Cui W, Pelling JC. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res. 1999;5:1007-1014.
14. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem. 2000;275:38953-38956.
15. Milella M, Estroy Z, Kornblau SM. et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 2002;99: 3461-3464.
16. Yu C, Krystal G, Varticovksi L, et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res. 2002;62:188-199.
17. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682.
18. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271: 12687-12690.
19. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155-162.
20. Gura T. How TRAIL kills cancer cells, but not normal cells [editorial]. Science. 1997;277:768.
21. French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med. 1999;5:146-147.
22. Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis. 2001;6:191-197.
23. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 2001;8:1066-1075.
24. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420-430.
25. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998;10:559-563.
26. Golstein P. Cell death: TRAIL and its receptors. Curr Biol. 1997;7:R750-R753.
27. Degli-Esposti M. To die or not to die: the quest of the TRAIL receptors. J Leukoc Biol. 1999;65:535-542.
28. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11:255-260.
29. Fiumara P, Younes A. CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies. Br J Haematol. 2001;113:265-274.
30. Green DR, Evan GI. A matter of life and death. Cancer Cell. 2002;1:19-30.
31. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000;102:1-4.
32. Snell V, Clodi K, Zhao S, et al. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol. 1997;99:618-624.
33. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. Concepts in the use of TRAIL/ Apo2L: an emerging biotherapy for myeloma and other neoplasias. Expert Opin Investig Drugs. 2001;10:1521-1530.
34. Nimmanapalli R, Porosnicu M, Nguyen D, et al. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res. 2001;7:350-357.
35. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia. 1999;13:1817-1824.
36. Clodi K, Younes A. Reed-Sternberg cells and the TNF family of receptors/ligands. Leuk Lymphoma. 1997;27:195-205.
37. Fiumara P, Snell V, Li Y, et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood. 2001; 98:2784-2790.
38. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85: 1-14.
39. Carbone A, Gloghini A. Diagnostic significance of CD40, CD40L, and CD26 expression in Hodgkin's disease and other lymphomas. Am J Clin Pathol. 1996;105:522-523.
40. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol. 1997;17:1535-1542.
41. Gruss HJ, Ulrich D, Braddy S, Armitage RJ, Dower SK. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur J Immunol. 1995;25:2083-2089.
42. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells, II: continuous cell lines. Leuk Lymphoma. 1993;9:1-25.
43. Clodi K, Asgary Z, Zhao S, et al. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol. 1998;103:270-275.
44. Younes A, Drach J, Katz R, et al. Growth inhibition of follicular small-cleaved-cell lymphoma cells in short-term culture by interleukin-3. Ann Oncol. 1994;5:265-268.
45. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 1975;66:188-193.
46. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998;273: 18623-18632.
47. Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood. 1995;85:780-789.
48. Gruss HJ, Kadin ME. Pathophysiology of Hodgkin's disease: functional and molecular aspects. Baillieres Clin Haematol. 1996;9:417-446.
49. Gruss HJ, Hirschstein D, Wright B, et al. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood. 1994;84:2305-2314.
50. Annunziata CM, Safiran YJ, Irving SG, Kasid UN, Cossman J. Hodgkin disease: pharmacologic intervention of the CD40-NFkappaB pathway by a protease inhibitor. Blood. 2000;96:2841-2848.
51. Mukhopadhyay A, Fiumara P, Li Y, Darnay BG, Aggarwal B, Younes A. Receptor activator of nuclear factor-κB (RANK) ligand activates mitogen-activated protein kinases signaling pathways in Hodgkin/Reed-Sternberg cells. Blood. 2002;99: 3485-3486.
52. Wendtner CM, Schmitt B, Gruss HJ, et al. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line. Cancer Res. 1995;55:4157-4161.
53. Townsend KJ, Trusty JL, Traupman MA, Eastman A, Craig RW. Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C. Oncogene. 1998;17:1223-1234.
54. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003;101:681-689.
55. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene. 2001;20:2122-2133.
56. Yamada H, Tada-Oikawa S, Uchida A, Kawanishi S. TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells. Biochem Biophys Res Commun. 1999;265:130-133.
57. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 2002;16:33-45.
58. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene. 2002;21:2283-2294.
59. Bin L, Li X, Xu LG, Shu HB. The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Lett, 2002;510: 37-40.
60. Munshi A, Pappas G, Honda T, et al. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene. 2001;20:3757-3765.